Hepatitis Antivirals Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Hepatitis Antivirals DMPK and Bioanalytical Services

Hepatitis antiviral bioanalysis sits at the junction of liver-directed antiviral exposure, prodrug activation, NS5A inhibitor distribution, DDI-risk interpretation, and minimal-metabolism nucleoside analog profiling. Sofosbuvir requires activation-aware method design, while ledipasvir and velpatasvir often raise distribution and interaction-risk questions. Entecavir and telbivudine shift the workflow toward parent-drug exposure and minimal-metabolism interpretation.

Creative Proteomics develops LC-MS/MS and DMPK workflows for hepatitis antivirals, including parent-drug quantification, CES/CDA/TP-linked sofosbuvir activation support, microsome/hepatocyte bioanalysis, in vivo sample analysis, distribution profiling, DDI-risk-focused study support, and custom hepatitis antiviral panel development.

Browse Hepatitis Antiviral Drug Index Request Custom Hepatitis Antiviral Support

Activation cascadeFrame sofosbuvir workflows around enzymatic activation rather than parent-only measurement.

DAA distributionEvaluate ledipasvir and velpatasvir with distribution and DDI-risk context in mind.

Minimal metabolismBuild parent-drug workflows for HBV nucleoside analogs with limited metabolism.

Hepatitis Antiviral Workflow Risks DMPK Strategy Map

🧬

Prodrug activation layerSofosbuvir studies may need CES, CDA, and TP-linked conversion logic before interpretation.

🧫

Liver-associated model choiceMicrosome, hepatocyte, and in vivo samples answer different hepatitis antiviral questions.

🔁

Distribution and DDI riskNS5A inhibitor workflows may be driven by exposure distribution and interaction-risk context.

📊

Parent-drug profilingMinimal-metabolism HBV analogs often require clean parent exposure and distribution readouts.

Liver-contextual hepatitis antiviral workflow design.Creative Proteomics connects prodrug activation, parent-drug bioanalysis, distribution profiling, DDI-risk interpretation, minimal-metabolism workflows, and custom hepatitis antiviral panels in one study-aware strategy.

Hepatitis Antiviral Drug Index

Find the Hepatitis Antiviral Compound Behind the Study

Hepatitis antiviral projects are usually defined by the role each compound plays in the liver-focused exposure story. Sofosbuvir is an activation-driven prodrug problem; ledipasvir and velpatasvir are distribution and DDI-risk entries; entecavir and telbivudine are cleaner parent-drug questions with minimal metabolism. Use the search bar, A–Z anchors, and field tags below to move from compound name to the right activation, distribution, DDI-risk, or minimal-metabolism workflow.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only hepatitis antivirals matching all selected values.

5 entries · Page 1 of 2

Analytical Pain Points

What Drives Assay Failure in Hepatitis Antiviral Studies?

Hepatitis antiviral workflows can fail when HCV direct-acting antivirals and HBV nucleoside analogs are treated as one uniform antiviral set. Sofosbuvir demands activation-chain thinking, NS5A inhibitors require distribution and DDI-risk context, and minimally metabolized HBV analogs need parent-drug exposure workflows that do not overcomplicate the biology.

Sofosbuvir Activation Cannot Be Reduced to Parent-Only Quantification

Sofosbuvir workflows may require CES, CDA, and TP-related activation logic. Measuring only the administered compound can miss the conversion question that gives the data its DMPK meaning.

Our responseActivation-aware LC-MS/MS workflows that support prodrug conversion, microsome/hepatocyte analysis, analyte selection, and parent-to-conversion-related interpretation.

Drug Metabolism & Biotransformation →

NS5A Inhibitor Studies Often Pivot on Distribution and DDI Risk

Ledipasvir and velpatasvir are not primarily broad MetID entries in this tag set. Their analytical value often comes from parent exposure, distribution behavior, and interaction-risk study context.

Our responseDistribution-focused bioanalysis and DDI-risk-aware method planning for in vivo samples, plasma/serum workflows, and comparative exposure studies.

Drug–Drug Interaction Support →

Minimal-Metabolism HBV Analogs Need Clean Parent-Drug Readouts

Entecavir and telbivudine can be better approached through parent-drug distribution rather than complex metabolite discovery. Overbuilding the assay around irrelevant transformation pathways can waste method-development effort.

Our responseParent-drug LC-MS/MS workflows with matrix-specific calibration, concentration-window planning, and distribution-oriented in vivo sample interpretation.

LC-MS/MS Quantification →

Liver-Relevant Models Must Be Matched to the Question

Microsome and hepatocyte systems are useful for activation and metabolism questions, while in vivo samples may be better suited to distribution, DDI-risk, or parent exposure analysis. Mixing these contexts can blur the study endpoint.

Our responseModel-aligned sample preparation and reporting that separate activation models, in vivo exposure studies, and matrix-specific distribution workflows.

Plasma & Serum Bioanalysis →

Hepatitis Antiviral Panels Must Balance Prodrugs, DAAs, and HBV Analogs

A panel containing sofosbuvir, NS5A inhibitors, and minimally metabolized nucleoside analogs can fail if it assumes shared extraction behavior, ionization, retention, or concentration windows.

Our responseCustom LC-MS/MS panels designed around analyte compatibility, extraction strategy, MRM transitions, matrix-matched calibration, internal standards, and panel-specific selectivity.

Custom Drug Panels →

Focused Service Paths

Four Practical Routes for Hepatitis Antiviral Studies

The analytical route should be selected according to the hepatitis antiviral question: prodrug activation, NS5A inhibitor distribution and DDI risk, minimal-metabolism parent exposure, or custom multi-antiviral panel development.

Sofosbuvir Prodrug Activation and Conversion Support

For studies where CES, CDA, TP, prodrug conversion, or activation-linked analyte selection defines the DMPK question.

Sofosbuvir activation workflows
Microsome / hepatocyte sample support
Parent-to-conversion analyte planning
Prodrug activation time-course analysis

Drug Metabolism & Biotransformation →

NS5A Inhibitor Distribution and DDI-Risk Bioanalysis

For ledipasvir and velpatasvir studies where distribution, parent exposure, interaction risk, or in vivo sample interpretation is central.

Ledipasvir exposure analysis
Velpatasvir exposure analysis
DDI-risk study support
Distribution-focused bioanalysis

Drug–Drug Interaction Support →

Minimal-Metabolism Parent-Drug Exposure Profiling

For entecavir, telbivudine, and related compounds where parent-drug distribution and in vivo sample behavior drive the assay.

Minimal-metabolism workflows
In vivo sample bioanalysis
Parent-drug quantification
Distribution-oriented interpretation

LC-MS/MS Quantification →

Custom Hepatitis Antiviral Panel Development

For studies involving multiple HCV/HBV antivirals, prodrugs, parent analytes, or chemically diverse compounds in one LC-MS/MS workflow.

Sofosbuvir / NS5A inhibitor panels
HBV nucleoside analog panels
Custom MRM planning
Matrix-matched calibration strategy

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Hepatitis Antiviral?

If you are working with an HCV direct-acting antiviral, HBV nucleoside analog, prodrug, active conversion-related analyte, DDI-risk study, liver-associated model, minimal-metabolism compound, or multi-antiviral panel, a standard parent-only LC-MS/MS method may not answer the study question.

Creative Proteomics develops custom LC-MS/MS and DMPK workflows for hepatitis antiviral research by defining the activation route, matrix type, expected concentration range, DDI-risk context, distribution objective, minimal-metabolism status, and panel compatibility before method development begins.

Target hepatitis antiviral

Activation or prodrug context

Matrix and concentration range

DDI-risk or distribution focus

Minimal-metabolism interpretation

Single-analyte or panel workflow